Exenatide Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: GLP-1 receptor metabolic pharmacology

Metabolic Research peptide SolutionExtended-release suspension verified

Also known as: Byetta, Bydureon (discontinued 2024)

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

5 ug/dose pen, 10 ug/dose pen, 2 mg extended-release dose

Storage

Follow formulation-specific prescribing information; unopened pens are refrigerated and must not be frozen

Solubility

Ready-to-use solution for immediate-release pens; the extended-release product uses a distinct microsphere suspension

Catalog Description

Exenatide, a synthetic version of exendin-4 (originally isolated from Gila monster venom), was the first GLP-1 receptor agonist approved by the FDA (Byetta, 2005) for type 2 diabetes, dosed twice daily. An extended-release once-weekly formulation (Bydureon) was later approved. the marketing authorization holder discontinued Byetta and Bydureon BCise in October 2024.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Mean terminal half-life is approximately 2.4 hours for immediate-release exenatide

Onset

Peak concentration occurs about two hours after SC immediate-release dosing; clinical metabolic effects are assessed over repeated dosing

Administration Routes (Research)

Reported Research Effects

Glucose-dependent insulin secretion
Slows gastric emptying
Historic first-in-class GLP-1 agonist

Reported Research Side Effects

Nausea
Vomiting
Diarrhea
Hypoglycemia with insulin secretagogues
Pancreatitis warning
Acute kidney injury risk

Data source: Current approved prescribing information

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

Weeks 1-4 or longer: 5 mcg twice daily; after at least 1 month, increase to 10 mcg twice daily if additional glycemic control is needed and tolerated [SC; Label-directed chronic use; Within 60 minutes before morning and evening meals]Source: BYETTA prescribing information
Extended-release exenatide: 2 mg once weekly with no titration ladder [SC; Label-directed chronic use; Weekly]Source: extended-release exenatide labeling

Research Interactions

Flagged Avoid / Caution Combinations (Research)

Other GLP-1 receptor agonists
Insulin secretagogues without monitored adjustment
Oral drugs requiring rapid gastrointestinal absorption near dosing

Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.

Research Notes

The prior semaglutide and tirzepatide stack entries were removed. Immediate-release and extended-release products have different strengths schedules and formulations.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

BYETTA prescribing information — DailyMed (NIH)
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=53d03c03-ebf7-418d-88a8-533eabd2ee4f

Byetta EPAR — European Medicines Agency
https://www.ema.europa.eu/en/medicines/human/EPAR/byetta

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.